PDCD1 and neoplasm: While the monotreatment with anti-PD-1 antibody resulted in a significant delay of tumor growth, the combination of miR-21–3p-AuNp and anti-PD-1 antibody could lead to more prominent delay of tumor progression as revealed by the alteration of tumor volume and tumor weight, which could be reversed by the administration with liproxstatin-1 (figure 6A–C).